EGRX Eagle Pharmaceuticals Inc.

52.61
-0.71  -1%
Previous Close 53.32
Open 53.38
Price To Book 4.11
Market Cap 720,757,000
Shares 13,700,000
Volume 137,616
Short Ratio
Av. Daily Volume 190,903

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pivotal trial data released October 30, 2018 did not meet primary endpoints.
Fulvestrant
Breast cancer
Tentative approval announced October 27, 2017. Full approval pending patent litigation with Eli Lilly.
PEMFEXY,
Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma
CRL issued July 26, 2017. Additional trial required.
Ryanodex
Exertional heat stroke (EHS)
Tentative approval July 2 2014. Teva has also received orphan drug and related pediatric exclusivity expiring in September 2015 and May 2016 for the CLL and NHL indications, respectively.
EP-3101 (bendamustine RTD)
Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphoma - cancer
CRL March 18 2016. FDA requested further characterization of bivalirudin-related substances in the drug product
KANGIO (bivalirudin injection)
Percutaneous Coronary Intervention (PCI) and Percutaneous Transluminal Coronary Angioplasty (PTCA)
Approved December 24, 2015.
Docetaxel Injection
Breast, non-small cell lung, prostate gastric adenocarcinoma, and head and neck cancer
Approved July 22, 2014 under priority review.
Ryanodex
Malignant hyperthermia - cancer
Intends to meet with FDA June 2019 to discuss path forward.
Ryanodex
Exertional heat stroke (EHS)
Data released May 7, 2019 noted lower incidence of brain damage.
Ryanodex
Nerve agent (NA) exposure

Latest News

  1. See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
  2. Here's Why I Think Eagle Pharmaceuticals (NASDAQ:EGRX) Might Deserve Your Attention Today
  3. Eagle Pharmaceuticals, Inc. to Present at Jefferies 2019 Global Healthcare Conference
  4. Edited Transcript of EGRX earnings conference call or presentation 7-May-19 12:30pm GMT
  5. Eagle Pharmaceuticals, Inc. to Present at 2019 RBC Capital Markets Global Healthcare Conference
  6. Hedge Funds Have Never Been More Bullish On Eagle Pharmaceuticals Inc (EGRX)
  7. Can Eagle Pharma Fly through its Oncology Trials
  8. Eagle Pharmaceuticals Inc (EGRX) Q1 2019 Earnings Call Transcript
  9. Eagle Pharmaceuticals (EGRX) Beats Q1 Earnings and Revenue Estimates
  10. Did You Miss Eagle Pharmaceuticals's (NASDAQ:EGRX) Whopping 457% Share Price Gain?
  11. Eagle Pharmaceuticals: 1Q Earnings Snapshot
  12. Eagle Pharmaceuticals, Inc. Reports First Quarter 2019 Results
  13. Eagle Pharmaceuticals Announces Positive Results of a Study Conducted in Partnership with the U.S. Military to Evaluate Neuroprotective Effects of RYANODEX for the Treatment of Nerve Agent Exposure
  14. Eagle Pharmaceuticals (EGRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
  15. Eagle Pharmaceuticals to Discuss First Quarter 2019 Financial Results on May 7, 2019
  16. New Strong Sell Stocks for April 22nd
  17. CMS Establishes Unique J-Code for BELRAPZO™ (Bendamustine 500mL Hydrochloride Injection)
  18. Eagle Pharmaceuticals, Inc. Expands Licensing Agreement for BENDEKA™ with Teva Pharmaceuticals International GmbH